Patents by Inventor Joacim Elmen

Joacim Elmen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210071181
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the mIRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: October 1, 2020
    Publication date: March 11, 2021
    Inventors: Joacim ELMEN, Phil KEARNEY, Sakari KAUPPINEN
  • Patent number: 10450564
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 22, 2019
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • Publication number: 20190071672
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: September 10, 2018
    Publication date: March 7, 2019
    Inventors: Joacim Elmen, Phil Kearney, Sakari Kauppinen
  • Publication number: 20180201928
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Application
    Filed: September 15, 2017
    Publication date: July 19, 2018
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • Publication number: 20180195062
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: September 13, 2017
    Publication date: July 12, 2018
    Inventors: Joacim Elmen, Phil Kearney, Sakari Kauppinen
  • Patent number: 9790493
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: October 17, 2017
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • Patent number: 9738894
    Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogs comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogs comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogs comprise at least one locked nucleic acid (LNA) monomer.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: August 22, 2017
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Joacim Elmen, Claes Wahlestedt, Zicai Liang, Anders M. Sorensen, Henrik Orum, Troels Koch
  • Publication number: 20170009237
    Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.
    Type: Application
    Filed: March 28, 2016
    Publication date: January 12, 2017
    Inventors: Joacim Elmen, Claes Wahlestedt, Zicai Liang, Anders M. Sorensen, Henrik Orum, Troels Koch
  • Patent number: 9297010
    Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogs comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogs comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogs comprise at least one locked nucleic acid (LNA) monomer.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: March 29, 2016
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Joacim Elmen, Claes Wahlestedt, Zicai Liang, Anders M. Sorensen, Henrik Orum, Troels Koch
  • Publication number: 20160060627
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: September 3, 2015
    Publication date: March 3, 2016
    Inventors: Joacim ELMEN, Phil Kearney, Sakari Kauppinen
  • Publication number: 20150299699
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Application
    Filed: October 29, 2014
    Publication date: October 22, 2015
    Inventors: Susanna OBAD, Sakari Kauppinen, Joacim Elmén, Morten Lindow, Markus Heidenblad
  • Patent number: 9133455
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogs into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: September 15, 2015
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Joacim Elmén, Phil Kearney, Sakari Kauppinen
  • Patent number: 8906871
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: December 9, 2014
    Assignee: Santaris Pharma A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmén, Morten Lindow, Markus Heidenblad
  • Publication number: 20140329883
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: April 4, 2014
    Publication date: November 6, 2014
    Applicant: Santaris Pharma A/S
    Inventors: Joacim ELMÉN, Phil Kearney, Sakari Kauppinen
  • Publication number: 20140235844
    Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.
    Type: Application
    Filed: February 11, 2014
    Publication date: August 21, 2014
    Applicant: Santaris Pharma A/S
    Inventors: Joacim Elmen, Claes Wahlestedt, Zicai Liang, Anders M. Sorensen, Henrik Orum, Troels Koch
  • Patent number: 8729250
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: May 20, 2014
    Inventors: Joacim Elmén, Phil Kearney, Sakari Kauppinen
  • Patent number: 8563528
    Abstract: The present invention relates to oligomer compounds (oligomers), which target PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for the treatment of certain medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: October 22, 2013
    Assignee: Santaris Pharma A/S
    Inventors: Ellen Marie Straarup, Niels Fisker Nielsen, Marie Lindholm, Joacim Elmèn
  • Patent number: 8440637
    Abstract: The present invention relate to the use of a combination of an inhibitor of miR-122 and an inhibitor of VLDL assembly, for the treatment of HCV, hyperlipidemia and hypercholesterolemia.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: May 14, 2013
    Assignee: Santaris Pharma A/S
    Inventor: Joacim Elmén
  • Patent number: 8288356
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: October 16, 2012
    Assignee: Santaris Pharma A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • Publication number: 20120238618
    Abstract: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.
    Type: Application
    Filed: March 8, 2012
    Publication date: September 20, 2012
    Applicant: Santaris Pharma A/S
    Inventors: Joacim Elmén, Phil Kearney, Sakari Kauppinen